Loading
Radiotherapy / Artificial Intelligence · Journal article
Annals of Oncology
Encouraging direction, but not yet definitive.
This multicohort analysis demonstrates that incidental thymic irradiation during lung cancer radiotherapy is independently associated with increased distant metastasis and mortality risk, with effect estimates suggesting 1.57–4.21% increased metastasis risk per 1 Gy of mean thymic dose. The association is strongest in patients with preserved baseline thymic function, supported by dose-dependent declines in imaging-based thymic health and lymphocyte counts. However, no randomized trial of thymus-sparing radiotherapy has yet been completed, and the observational design cannot exclude confounding or reverse causation.
Multicohort observational analysis; one component from a phase III randomized controlled trial. Patients with non-small cell lung cancer treated with radiotherapy-based regimens; eligibility criteria and specific trial inclusion/exclusion not detailed in source.. Intervention: Incidental thymic radiation exposure quantified by mean thymic dose (MTD) during standard radiotherapy planning for NSCLC.. Compared with: Lower thymic radiation dose; stratified by baseline thymic health status.. n = 1,107. RTOG-0617 trial; HARVARD-CRT and HARVARD-DURVA (Harvard-affiliated institutions implied by name; specific centres not stated)..
1 Gy increase in mean thymic dose associated with distant metastasis risk increase of 1.57–4.21% across cohorts (RTOG-0617 aHR=1.29, P=0.0028; HARVARD-CRT aHR=1.33, P=0.011; HARVARD-DURVA aHR=1.95, P=0.007) Preserved thymic health prior to radiotherapy identified as a modifier of thymic radiation risk; no significant associations in patients with impaired baseline thymic health One-year follow-up imaging demonstrated dose-dependent declines in thymic health and lower circulating lymphocyte counts consistent with immune compromise
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest clinicians should consider thymic dose as a secondary constraint during radiotherapy planning for NSCLC, particularly in patients with preserved thymic function at baseline, if thymus-sparing does not compromise tumor coverage. However, this remains observational evidence; a randomized trial of thymus-sparing radiotherapy is needed before changing standard practice.
Multicohort observational analysis with consistent dose-response associations across three independent cohorts and plausible biological mechanism, but lacks randomized evidence of thymus-sparing intervention efficacy.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest clinicians should consider thymic dose as a secondary constraint during radiotherapy planning for NSCLC, particularly in patients with preserved thymic function at baseline, if thymus-sparing does not compromise tumor coverage. However, this remains observational evidence; a randomized trial of thymus-sparing radiotherapy is needed before changing standard practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Emerging evidence indicates the functional importance of the thymus in adult health and may influence oncologic outcomes, yet current radiotherapy (RT) practice does not consider the thymus as an organ of interest. Because RT may incidentally expose the thymus to radiation, we hypothesized that thymic radiation dose is negatively associated with major clinical outcomes.Patients and methods. This multicohort analysis included 1,107 patients with non-small cell lung cancer (NSCLC), including the phase III RTOG-0617 trial (n=460) and two independent real-world cohorts of patients treated with chemoradiotherapy alone (n=422; HARVARD-CRT) or in combination with consolidation immunotherapy (n=225; HARVARD-DURVA). We quantified thymic function using a deep-learning system that assessed thymic radiographic characteristics as a proxy for thymic function. Mean Thymic Dose (MTD) was used to measure thymic radiation exposure.Results. Incidental thymic irradiation was associated with increased risk of distant metastases after confounding adjustments. Concretely, a 1Gy increase in MTD was associated with an increased distant metastasis risk of 1.57-4.21% (RTOG-0617: adjusted hazard-ratio [aHR]=1.29; P=0.0028; HARVARD-CRT: aHR=1.33; P=0.011; HARVARD-DURVA: aHR=1.95; P=0.007). In Thymic-Health-stratified analysis, patients with preserved Thymic Health prior to radiotherapy appeared to be at particularly greater risk, whereas no significant associations emerged in patients with impaired Thymic Health. One-year follow-up imaging demonstrated dose-dependent declines in thymic health and lower circulating lymphocyte counts, consistent with a possible biological link between thymic irradiation and immune competence loss. An exploratory feasibility study suggested that re-optimizing RT planning for thymic sparing can be achieved without compromising tumor coverage or cardiopulmonary constraints.Conclusions. Thymic radiation exposure was independently associated with higher risks of metastasis and death in NSCLC patients, especially in those with preserved thymic function. These findings raise awareness towards considering the thymus as an organ of interest in radiotherapy and suggest that thymus-sparing strategies may help preserve immune health and improve patient outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.